Commercial terms and exact-model provenance remain subject to current source checks.
Reader service card
Practice ownership and buying signals
OwnershipNo reader benchmark yet
EvaluationNo reader benchmark yet
Replacement intentNo reader benchmark yet
SponsorNo sponsor
Device Pulse is not collecting these actions on this page. Disabled controls show the planned reader service without creating a response, lead, sponsor relationship, or vendor request.
Activation requires a separate consent notice, controlled storage, duplicate and suppression rules, retention and deletion controls, named vendor-transfer disclosure, and an audit log. Newsletter signup does not activate these controls.
Overview
xeo+ is a Cutera platform in the vascular/pigment category. The manufacturer describes it as using Configurable laser and pulsed-light platform with indication-specific handpieces for hair-bearing areas, vascular lesions, benign pigmented lesions, skin revitalization areas. Those specifications are company-reported, not an independent performance conclusion.
Cutera describes xeo+ as a configurable platform for more than 25 concerns. The exact capability depends on installed handpieces and current labeling. The cited FDA records establish only the device names, classifications, or indications stated in those records. They do not establish comparative superiority, outcomes for every patient, or current commercial terms.
Before purchase, request the exact model, cleared indications, software version, handpieces, service coverage, training, and a written quote. Pricing and operating economics remain unknown where a current source packet was not available.
TREATMENT AREAS
Hair-bearing areas, Vascular lesions, Benign pigmented lesions, Skin revitalization areas
TREATMENT TIME
Varies by installed handpiece and treatment area
SESSIONS
Depends on handpiece, indication, and patient response
PER SESSION
Practice-set; no verified range
CONSUMABLES/YR
Configuration-specific; current quote required
MAINTENANCE/YR
Service quote required
Pros & Cons
Pros
FDA database names the current xeo+ Family and decision date
Configurable handpieces can cover several common aesthetic workflows
Cutera publishes detailed indications and safety information for the xeo family
One console can reduce duplicated hardware when the required handpieces are included
Cons
A platform name does not reveal the quoted handpiece configuration
Public acquisition and upgrade pricing were not reconciled
Laser and pulsed-light risks include burns, pigment change, scarring, and unintended hair effects
Buyers need written confirmation of included handpieces, software, training, service, and transfer terms
Clinical Evidence
FDA and manufacturer records establish the platform and indications. Device Pulse has not reconciled a configuration-specific comparative evidence table.
This profile does not treat a clearance record or manufacturer page as proof of superior outcomes. Match each clinical claim to the exact model, indication, study design, sample size, source date, and funding disclosure.
The current packet supports product identification and the limited regulatory statements shown here. Independent comparative effectiveness, local demand, and practice economics remain open diligence questions.
ROI Analysis
Device Pulse is not publishing a payback estimate for xeo+ because current transaction price, financing, service, consumables, staffing, and local patient demand have not been independently verified.
Build the decision from your written quote. Model conservative monthly treatment volume, realized revenue per treatment, consumables, operator time, service, downtime, financing, and patient-acquisition cost. Run a downside case before using the model in a purchase decision.
A manufacturer projection is an input to test, not a forecast. Ask for every assumption in writing and compare it with your scheduling capacity and historical conversion data.
Best For
Practices that need several laser and light workflows from one console and will compare the exact quoted handpiece package rather than the platform name alone.
Use that as a short-list hypothesis. Confirm the exact indication, patient mix, operator training, local service, workflow, and written commercial terms before deciding that the platform fits the practice.
Buying Guide
Request a written, model-specific quote for xeo+. Separate the console, handpieces, software, training, installation, warranty, service, and recurring supplies or licensing.
Confirm the serial number, current software, cleared indications, ownership-transfer terms, parts availability, response time, and local service provider. Do not assume a product-page feature applies to every configuration.
Ask Cutera to identify which statements are specifications, which are company-reported claims, and which are supported by independent clinical evidence. Keep those records with the final contract.
Alternatives to review
Use these profiles to build a short list. An alternative listing is not a claim of equivalence or superiority.
BBL HEROic: Established dermatology or aesthetic practices comparing a multi-application light platform and prepared to verify the exact console, filters, current labeling,
NEW Manufacturer quote required · USED No reconciled dated sample
Nordlys: Dermatology practices that want a single workhorse platform covering vascular, pigmented, hair removal, and light resurfacing at a moderate capital cost. Starte
Excel V+: Dermatology practices that want dual-wavelength vascular laser capability at lower cost than VBeam Prima. Buyers comfortable with the Cutera situation and exper
GentleMax Pro Plus: High-volume med spas and dermatology practices where hair removal is a top revenue line. Practices serving diverse patient skin types that need both Alexandrite
A current acquisition price was not published in the reviewed source packet. Request a written quote from Cutera that separates the console, handpieces, software, training, installation, warranty, service, and recurring supplies.
What is the FDA status of xeo+?
FDA Devices@FDA lists the xeo+ Family under K233237 with a substantially equivalent decision dated December 15, 2023.
What evidence supports this xeo+ profile?
FDA and manufacturer records establish the platform and indications. Device Pulse has not reconciled a configuration-specific comparative evidence table. The source packet separates FDA public records from manufacturer-reported product information. It does not establish comparative superiority.
Which practices should evaluate xeo+?
Practices that need several laser and light workflows from one console and will compare the exact quoted handpiece package rather than the platform name alone. That is an editorial fit question, not a clinical or financial conclusion.
What should a buyer verify before ordering xeo+?
Verify the exact model, cleared indications, handpieces, software, serial-number history, training, service response, warranty, ownership-transfer terms, recurring supplies, and every commercial assumption in writing.
What are the main limitations in this xeo+ profile?
Current limitations include: A platform name does not reveal the quoted handpiece configuration; Public acquisition and upgrade pricing were not reconciled; Laser and pulsed-light risks include burns, pigment change, scarring, and unintended hair effects. Recheck the dated primary sources before using the profile in a purchase decision.
Get the Device Quote Review Kit
Open the printable buyer checklist now, then get the planned Tuesday brief with price, FDA, safety, evidence, and manufacturer signals.
Free kit available immediately. Planned Tuesday brief. Unsubscribe anytime. Privacy.
